Search Within

Joachim Yahalom

  1. "Matthew Matasar"
Formats
  1. Meeting Abstract (22)
  2. Journal Article (16)
  3. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (39)
  2. Department of Medicine (39)
  3. Hematologic Malignancies, Division of (39)
  4. Lymphoma (39)
  5. Radiation Oncology, Department of (39)
  6. Survivorship Research (39)

More Groups

People
  1. Matthew Matasar (39)
  2. Alison Moskowitz (37)
  3. Andrew Zelenetz (34)
  4. Paul Hamlin (33)
  5. Ariela Noy (32)
  6. David Straus (31)

More People

Years
  1. 2024 (1)
  2. 2023 (3)
  3. 2022 (3)
  4. 2021 (6)
  5. 2020 (5)
  6. 2019 (6)

More Years

Publications
  1. Blood (16)
  2. Hematological Oncology (6)
  3. Journal of Clinical Oncology (4)
  4. Blood Advances (3)
  5. Biology of Blood and Marrow Transplantation (2)
  6. British Journal of Haematology (2)

More Publications

Publishers
  1. American Society of Hematology (19)
  2. Wiley Blackwell (6)
  3. American Society of Clinical Oncology (4)
  4. Elsevier Inc. (3)
  5. Ferrata Storti Foundation (2)
  6. John Wiley & Sons (2)

More Publishers

Results (39)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A pilot study of brentuximab vedotin combined with AVD chemotherapy and radiotherapy in patients with newly diagnosed early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L. E.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Constine, L. S.; Dandapani, S.; Drill, E.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Safety and early data from a phase II trial of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (Hl) and follicular lymphoma (FL)
    Meeting Abstract

    Sermer, D.; Vardhana, S.; Batlevi, C.; Hamilton, A.; Moskowitz, A.; Caron, P.; Moskowitz, C.; Matasar, M.; Biggar, E.; Leung, E.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Incidence and treatment outcomes of patients with transformed marginal zone lymphoma treated with RCHOP‐like regimens
    Meeting Abstract

    Rajeeve, S.; Bobillo, S. V.; Zelenetz, A. D.; Straus, D. J.; Palomba, M. L.; Noy, A.; Horwitz, S. M.; Moskowitz, A. J.; Hamlin, P. A.; Matasar, M. J.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of stage I diffuse large B cell lymphoma (DLBCL) in the rituximab‐era
    Meeting Abstract

    Bobillo, S.; Joffe, E.; Lavery, J.; Noy, A.; Palomba, L.; Straus, D. J.; Kumar, A.; Batlevi, C.; Horwitz, S.; Moskowitz, A.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Outcomes of relapsed and refractory primary mediastinal (thymic) large B cell lymphoma treated with second-line therapy and intent to transplant
    Journal Article

    Vardhana, S.; Hamlin, P. A.; Yang, J.; Zelenetz, A.; Sauter, C. S.; Matasar, M. J.; Ni, A.; Yahalom, J.; Moskowitz, C. H.
    Biology of Blood and Marrow Transplantation (2018)

    Fulltext@MSK | Save
  • Early toxicities associated with radiation based conditioning for relapsed/refractory Hodgkin lymphoma patients undergoing high dose therapy and autologous stem cell transplantation (HDT-ASCT)
    Meeting Abstract

    Shah, G. L.; Scordo, M.; Devlin, S. M.; Yahalom, J.; Matasar, M. J.; Moskowitz, A.; Giralt, S. A.; Moskowitz, C. H.
    Biology of Blood and Marrow Transplantation (2017)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Chen, R. W.; Constine, L. S.; Courtien, A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Cadzin, B. R.; Fox, S. Y.; Gerecitano, J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R.; Budde, E.; Barr, P. M.; Batlevi, C. L.; Chen, R.; Constine, L. S.; Courtien, A. I.; Dandapani, S. V.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Baseline metabolic tumor volume is an independent prognostic factor for relapsed and refractory Hodgkin lymphoma patients receiving PET-adapted salvage therapy with brentuximab vedotin and augmented ICE
    Meeting Abstract

    Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save